Roflumilast restores cAMP/PKA/CREB signaling axis for FtMt-mediated tumor inhibition of ovarian cancer.

Gong, Shipeng; Chen, Yongning; Meng, Fanliang; Zhang, Yadi; Wu, Huan; Wu, Fei

Gong, Shipeng; Chen, Yongning; Meng, Fanliang; Zhang, Yadi; Wu, Huan; Wu, Fei.

Afiliación

Gong S; Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Chen Y; Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Meng F; Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Zhang Y; Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Wu H; Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, P.R. China.
Wu F; Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.

Oncotarget ; 8(68): 112341-112353, 2017 Dec 22.

Article en En | MEDLINE | ID: mdl-29348829

Palabras clave

CREB; FtMt; cAMP; ovarian cancer; roflumilast

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article